{
    "clinical_study": {
        "@rank": "48794", 
        "brief_summary": {
            "textblock": "Patients with Parkinson's disease are missing the chemical neurotransmitter dopamine.  This\n      occurs as a result of destructive changes in an area of the brain responsible for making\n      dopamine, the basal ganglia.  Patients with the disease experience, rigid muscles, stooped\n      posture, and a shuffling-type walk (gait).\n\n      In this study researchers plan to evaluate the effectiveness of the drug eliprodil for the\n      treatment of Parkinson's Disease.  Eliprodil works by blocking special receptors (NMDA) that\n      are associated with the symptoms of Parkinson's Disease."
        }, 
        "brief_title": "Treatment of Parkinson's Disease With Eliprodil", 
        "completion_date": "January 2001", 
        "condition": [
            "Movement Disorders", 
            "Parkinson Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Movement Disorders", 
                "Parkinson Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "The objectives of this study are to evaluate the acute effects of the NR2B subtype-selective\n      NMDA antagonist eliprodil on levodopa-associated motor response complications in patients\n      with advanced Parkinson's Disease (PD)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "All patients will carry a diagnosis of idiopathic Parkinson's Disease based on the\n        presence of a characteristic clinical history and neurologic findings.  Most will have\n        relatively advanced disease with associated motor response complications.\n\n        Males and females between the ages of 18-75.\n\n        No presence or history of any medical condition that can reasonably be expected to subject\n        the patient to unwarranted risk.\n\n        No patients with baseline QTc prolongation (greater than 440 msec).\n\n        No pregnant women nor those not practicing effective means of birth control."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "20", 
        "firstreceived_date": "November 3, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001929", 
            "org_study_id": "990078", 
            "secondary_id": "99-N-0078"
        }, 
        "intervention": {
            "intervention_name": "Eliprodil", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Excitatory Amino Acid Antagonists", 
                "Eliprodil"
            ]
        }, 
        "keyword": [
            "Dyskinesias", 
            "Glutamate Antagonist", 
            "Levodopa"
        ], 
        "lastchanged_date": "March 3, 2008", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "National Institute of Neurological Disorders and Stroke (NINDS)"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "NMDA-Receptor Blockade With Eliprodil in Parkinson's Disease", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "reference": [
            {
                "PMID": "2402638", 
                "citation": "Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science. 1990 Sep 21;249(4975):1436-8."
            }, 
            {
                "PMID": "2586750", 
                "citation": "Mitchell IJ, Clarke CE, Boyce S, Robertson RG, Peggs D, Sambrook MA, Crossman AR. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience. 1989;32(1):213-26."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001929"
        }, 
        "source": "National Institutes of Health Clinical Center (CC)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Neurological Disorders and Stroke (NINDS)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "March 1999", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2000"
    }, 
    "geocoordinates": {
        "National Institute of Neurological Disorders and Stroke (NINDS)": "38.985 -77.095"
    }
}